Practical synthesis of 6-Amino-1-hydroxy-2,1-benzoxaborolane: A key intermediate of DNDI-6148

High-throughput screening of small-molecules libraries identified antibacterials against clinically relevant multidrug-resistant A. baumannii and K. pneumoniae

Towards enhanced control of mycetoma: a roadmap to achieve the UN’s sustainable development goals by 2030

Bioavailability of three novel oral, sustained-release pellets, relative to an immediate-release tablet containing 500 mg flucytosine: A randomized, open-label, crossover study in healthy volunteers

8 de mayo de 2024 – 9 de mayo de 2023, GMT-3

Buenos Aires, Argentina

XI Reunión Plenaria de la Plataforma Chagas

A sample-centric and knowledge-driven computational framework for natural products drug discovery

Involving patients in drug development for Neglected Tropical Diseases (NTDs): A qualitative study exploring and incorporating preferences of patients with cutaneous leishmaniasis into Target Product Profile development

Infobae – ‘Día Mundial de las Enfermedades Tropicales Desatendidas: qué son y por qué es importante prevenir y controlar los brotes’

26 de febrero de 2024, 8:00 am, GMT-3

Online

La enfermedad fúngica: una amenaza global oculta por olvidada

Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains

Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens

Population pharmacokinetics of pediatric lopinavir/ritonavir oral pellets in children living with HIV in Africa

La Tercera – ‘Luis Emilio Pizarro, el médico chileno que emigró a África y logró el título de Caballero y el Premio Princesa de Asturias’

Cooperativa CL – ‘Las «enfermedades desatendidas» tienen como principales víctimas a quienes sufren pobreza extrema’

Ensayo clínico comprueba la tolerabilidad del medicamento fexinidazol en el tratamiento de la enfermedad de Chagas

Efficacy and safety of fexinidazole for treatment of chronic indeterminate Chagas disease (FEXI-12): a multicentre, randomised, double-blind, phase 2 trial